SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

Simple item page
dc.contributor.authorEfe, Cumali
dc.contributor.authorTaşçılar, Koray
dc.contributor.authorGerussi, Alessio
dc.contributor.authorBolis, Francesca
dc.contributor.authorLammert, Craig
dc.contributor.authorEbik, Berat
dc.contributor.authorStättermayer, Albert Friedrich
dc.contributor.authorCengiz, Mustafa
dc.contributor.authorGökçe, Dilara Turan
dc.contributor.authorCristoferi, Laura
dc.contributor.authorPeralta, Mirta
dc.contributor.authorMassoumi, Hatef
dc.contributor.authorMontes, Pedro
dc.contributor.authorCerda, Eira
dc.contributor.authorRigamonti, Cristina
dc.contributor.authorYapalı, Suna
dc.contributor.authorAdali, Gupse
dc.contributor.authorÇalışkan, Ali Rıza
dc.contributor.authorBalaban, Yasemin
dc.contributor.authorEren, Fatih
dc.contributor.authorEşkazan, Tuğçe
dc.contributor.authorBarutçu, Sezgin
dc.contributor.authorLytvyak, Ellina
dc.contributor.authorZazueta, Godolfino Miranda
dc.contributor.authorKayhan, Meral Akdogan
dc.contributor.authorHeurgue-Berlot, Alexandra
dc.contributor.authorDe Martin, Eleonora
dc.contributor.authorYavuz, Ahmet
dc.contributor.authorBıyık, Murat
dc.contributor.authorNarro, Graciela Castro
dc.contributor.authorDuman, Serkan
dc.contributor.authorHernandez, Nelia
dc.contributor.authorGatselis, Nikolaos K.
dc.contributor.authorAguirre, Jonathan
dc.contributor.authorIdilman, Ramazan
dc.contributor.authorSilva, Marcelo
dc.contributor.authorMendizabal, Manuel
dc.contributor.authorAtay, Kadri
dc.contributor.authorGüzelbulut, Fatih
dc.contributor.authorDhanasekaran, Renumathy
dc.contributor.authorMontano-Loza, Aldo J.
dc.contributor.authorDalekos, George N.
dc.contributor.authorRidruejo, Ezequiel
dc.contributor.authorInvernizzi, Pietro
dc.contributor.authorWahlin, Staffan
dc.contributor.departmentMedicine, School of Medicine
dc.date.accessioned2024-06-06T20:03:57Z
dc.date.available2024-06-06T20:03:57Z
dc.date.issued2022-10
dc.description.abstractBackground Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17–85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10–0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11–0.35). Conclusions SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.
dc.eprint.versionFinal published version
dc.identifier.citationEfe, C., Taşçılar, K., Gerussi, A., Bolis, F., Lammert, C., Ebik, B., Stättermayer, A. F., Cengiz, M., Gökçe, D. T., Cristoferi, L., Peralta, M., Massoumi, H., Montes, P., Cerda, E., Rigamonti, C., Yapalı, S., Adali, G., Çalışkan, A. R., Balaban, Y., … Wahlin, S. (2022). SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis. Journal of Autoimmunity, 132, 102906. https://doi.org/10.1016/j.jaut.2022.102906
dc.identifier.urihttps://hdl.handle.net/1805/41279
dc.language.isoen_US
dc.publisherElsevier
dc.relation.isversionof10.1016/j.jaut.2022.102906
dc.relation.journalJournal of Autoimmunity
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectLiver failure
dc.subjectBreakthrough infection
dc.subjectImmunosuppression
dc.subjectVaccine
dc.subjectAutoimmunity
dc.titleSARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis
dc.typeArticle
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448709/
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Efe2022SARS-CoV-2-PubP.pdf
Size:
661.67 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles